drugset
drugset / Trial / NCT01568775

Pharmacokinetics, Safety and Tolerability of Aliskiren (SPP100) in Patients With End Stage Renal Disease on Hemodialysis and Matched Healthy Subjects

NCT01568775 ↗

Phase 1 Completed 12 enrolled Novartis
NaSingle-groupOpen-label

Summary

This study will assess the pharmacokinetics, safety and tolerability of aliskiren in healthy subjects and patients with End Stage Renal Disease on hemodialysis.

Timeline

Start
2010-06
Primary completion
2010-09
Completion
2010-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Aliskiren Small molecule 300 mg —

Indications

end stage renal failure